Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tønnesen, P.
Right arrow Articles by Bremann, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tønnesen, P.
Right arrow Articles by Bremann, L.
(Chest. 2006;130:334-342.)
© 2006 American College of Chest Physicians

Nurse-Conducted Smoking Cessation in Patients With COPD Using Nicotine Sublingual Tablets and Behavioral Support*

Philip Tønnesen, MD; Kim Mikkelsen, MD and Linda Bremann, RN

* From the Department of Pulmonary Medicine, Gentofte Hospital, Hellerup, Denmark.

Correspondence to: Philip Tønnesen, MD, Department of Pulmonary Medicine Y, Gentofte Hospital, Niels Andersensvej 65, 2900 Hellerup, Denmark; e-mail: philipt{at}dadlnet.dk

Abstract

Context: Few studies have examined the effect of nicotine replacement therapy (NRT) in COPD patients.

Study objective: To evaluate the efficacy of nicotine sublingual tablets and two levels of support for smoking cessation in COPD patients.

Design: Double-blind, multicenter, placebo-controlled smoking cessation trial.

Setting: Pulmonary outpatient clinics.

Patients: Three hundred seventy COPD patients who smoked a mean of 19.6 cigarettes per day (mean, 42.7 pack-years; mean FEV1, 56% of predicted).

Interventions: Nicotine sublingual tablet or placebo for 12 weeks combined with either low support (four visits plus six telephone calls) or high support (seven visits plus five telephone calls) provided by nurses.

Measurements: Carbon monoxide-verified abstinence rates and St. George Respiratory Questionnaire (SGRQ) assessed at 6 months and 12 months.

Results: Two hundred eighty-eight of 370 patients were evaluable for the final study end points. Smoking cessation rates were statistically significantly superior with sublingual nicotine vs placebo for all measures of abstinence: 6-month point prevalence, 23% vs 10%; 12-month point prevalence, 17% vs 10%. There was no significant difference in effect between low vs high behavioral support. The SGRQ score improved significantly in abstainers vs nonabstainers; the changes in mean scores were –10.9 vs – 2.9 for total score, and – 28.6 vs – 2.3 for symptom score, respectively.

Conclusions: This trial demonstrated the long-term efficacy of NRT for cessation for the general population of COPD smokers, regardless of daily cigarette consumption. Cessation success rates were in the same range as in healthy smokers, and abstinence improved SGRQ scores. NRT should be used to aid cessation in all smokers with COPD, regardless of disease severity and number of cigarettes smoked.

Key Words: behavioral support • COPD • lung function • nicotine sublingual tablet • quality of life • smoking cessation • smoking reduction




eLetters:

Read all eLetters

It's unlikely this NRT study was blind
John R. Polito
Chest Online, 15 Aug 2006 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.